← Eichor
Study identifier: NCT07346833 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis

Condition: Toxoplasmosis  ·  Sponsor: Benha University

PhaseN/A
Planned participants55
Who can joinFemale, 18 Years to 50 Years
Healthy volunteersNo

About this study

Chronic Toxoplasma gondii (T. gondii) infection is a widespread condition that can negatively affect brain function and is considered a risk factor for various psychiatric conditions, including depression and schizophrenia. This prospective observational study aims to investigate the expression levels of specific circulating microRNAs (miRNAs) in women diagnosed with schizophrenia, major depressive disorder, or bipolar disorder who also have chronic toxoplasmosis. By comparing these levels to patients without the infection, the study seeks to determine if these miRNAs can serve as biological markers to help differentiate between specific psychological disorders and identify the impact of chronic toxoplasmosis on mental health.

This description comes directly from the study's public registry record.

Talk to the study team

Heba Abo El Ela, MD  ·  01062702236  ·  b.checked88@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Benha faculty of MedicineBanhā, El Qalyoubia, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07346833